The SMART C-CDA Collaborative

1. OUTREACH

- 107 Vendors contacted
- 44 Responses
- 22 Technologies Represented (Most aligned with MU 2 requirements)
- 10 Group Meetings

What's hard? How to improve?

- Via webinars & online discussions

2. EVALUATION*

SMART C-CDA SCORECARD†

<table>
<thead>
<tr>
<th>Score Range</th>
<th>Number of Documents</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–30</td>
<td>3</td>
</tr>
<tr>
<td>31–60</td>
<td>3</td>
</tr>
<tr>
<td>61–70</td>
<td>6</td>
</tr>
<tr>
<td>71–80</td>
<td>1</td>
</tr>
<tr>
<td>81–90</td>
<td>3</td>
</tr>
<tr>
<td>91–100</td>
<td>2</td>
</tr>
</tbody>
</table>

MISSING DATA

- Medication Sig: 72%
- Allergy Severity: 55%
- Marital Status: 44%
- Result Interpretation: 44%
- Med Route: 28%

TERMINOLOGY

- All Problems in SNOMED: 67%
- Pre-Coordinated Meds in RxNorm: 53%
- Codified Allergic Reactions: 44%
- Uses UCUM for Results & Vitals: 39%

ERRORS

Example: Excess Precision

```xml
<effectiveTime value="20131202000000+500" />
```

- Trailing zeroes present when only date known
- Did event really happen at stroke of midnight?

Full error list: bit.ly/smart-ccda-findings, pages 5–9

†SMART C-CDA Scorecard: ccda-scorecard.smartplatforms.org

3. IMPROVEMENT

930 Minutes Spent with 11 Individual Vendors reviewing document quality

6 Key Challenges

1. Smoking history
2. Problem status & timing
3. Medication dose & timing
4. Medication allergies & reactions
5. Highly structured lab results
6. Highly structured vital signs

Improving Interoperability

© 2014 SMART Platforms. SMART Platforms Project is an ONC-funded research project at Harvard Medical School/Boston Children's Hospital. SMART and Lantana collaborated with EMR/HIE vendors to perform a detailed review of vendors’ Meaningful Use Stage 2 Consolidated-CDA documents. More at smartplatforms.org/2013/07/introducing-the-smart-c-cda-collaborative/.